Background {#Sec1}
==========

Human papillomavirus (HPV) is a very common sexually transmitted infection which is acquired through body fluids and skin-to-skin contact \[[@CR1]\]. It has been known as the causal agent of cervical cancer \[[@CR2]\]. In sub-Saharan Africa, the incidence of cervical cancer has reached up to 40.7 cases per 100,000 women and it is the second cause of death among cancers affecting women \[[@CR3], [@CR4]\]. In HIV infected women the risk of acquiring HPV is even higher due to immune suppression caused by HIV infection which has the same epidemiological pattern as HPV in sub-Saharan Africa \[[@CR5], [@CR6]\]. In most of these cases infection with multiple genotypes has been found to predominate \[[@CR5], [@CR7]--[@CR13]\].

Using molecular techniques, different HPV genotypes have been identified and categorized as high risk (HR) genotypes that are considered to be carcinogenic. These include HPV- 16, 18, 31, 33, 35, 95, 45, 51, 52, 56, 58, 59, 68, 73 and 82; and are considered to cause approximately 95 % of cervical cancers \[[@CR14]\]. Human papilloma virus genotypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and cp 6108 have been classified as low risk (LR); majority of these have been found to cause genital warts \[[@CR15]\]. Vaccines for HPV are available in some countries and have been found to be effective in reducing infection and its associated consequences \[[@CR16]\].

As reported earlier in Africa, women particularly those who are HIV infected are under-represented in the global estimate of HPV genotypes \[[@CR17]\]. This necessitates the need to emphasize HPV screening programs for understanding its epidemiology and effective control. Here we document varieties of HPV genotypes associated with cervical squamous intraepithelial lesions (SIL) and associated factors among HIV- infected women at Bugando Medical Centre, Mwanza-Tanzania underscoring the importance of focused control strategies to prevent cervical cancer in developing countries.

Methods {#Sec2}
=======

Study design, site and population {#Sec3}
---------------------------------

A cross sectional hospital based study involving 255 HIV infected women was conducted between August and October, 2014 at Bugando Medical Centre (BMC) HIV care and treatment clinic (CTC). The clinic attends patients who are on antiretroviral therapy (ART) and those who have not started ART. The CTC provides routine Papanicolaou (PAP) smear and gynaecological services with no routine screening of HPV. An average of 80 revisiting HIV infected women are seen per day \[[@CR18]\].

Patient selection, socio-demographic and clinical information {#Sec4}
-------------------------------------------------------------

The study included all HIV infected women aged \>18 years attending the CTC during the study period while excluding women who underwent wedge resection of the cervix and those with missed CD4 counts within 3 months of specimen collection. Socio-demographic and relevant clinical information collected were number of sexual partners, parity, marital status, age at 1st sexual debut, history of STI, history of genital warts, contraceptive use, and CD4 counts.

Sample collection and Laboratory procedures {#Sec5}
-------------------------------------------

Cervical exfoliated cells from the ectocervix and endocervix were obtained using cytobrush; there after the tip of the cytobrush was placed into a transport medium and stored at -10 °C until processing. Papanicolaou (PAP) smear was also taken, processed and interpreted based on the revised 2001 Bethesda system \[[@CR19]\].

Detection of HPV DNA {#Sec6}
--------------------

After vigorous vortexing of transport media, cytobrush was removed and 200 μl of sample was used for nucleic acid extraction with the MagNaPure LC DNA Large Volume Kit on a MagNaPure LC instrument (Roche Diagnostics, Mannheim, Germany) with elution volume set at 100 μl. For the detection of HPV DNA, two different end-point PCR assays (GEN-1 and GEN-2) were done as previously described \[[@CR20]\]. Both assays were done using primers targeting sequences which are conserved among a broad range of HPV genotypes, including all major genital HPV genotypes (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). These primers amplify fragments of approximately 460 bp for GEN-1 and 220 bp for GEN-2. All PCR products were sequenced (Eurofins Genomics, Ebersberg, Germany); for sequencing of the GEN-1 PCR products, only primer CP4 was used, whereas for GEN-2 PCR products both PPF1 and PPR2 primers were used as previously described \[[@CR20]\]. After editing the sequence files using Vector NTI Advance 9 software (Life Technologies, Darmstadt, Germany), sequences were subjected to BLAST search (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to identify the HPV genotypes. The efficiency of nucleic acid extraction was controlled by a real-time PCR assay from our routine diagnostics simultaneously targeting human cytomegalovirus (HCMV) and the human albumin gene.Table 1Sequences of primers and probes for HPV detection and controlsNameSequenceTargetHPV GEN1 PCR CP45´-ATG GTA CAR TGG GCA TWT GA-3´HPV E1 (nt 1942-1961) CP55´-GAG GYT GCA ACC AAA AMT GRC-3´HPV E1 (nt 2400-2378)HPV GEN2 PCR PPF15´-AAC AAT GTG TAG ACA TTA TAA ACG AGC-3´HPVE1 (nt 2082-2108) PPR25´-ATT AAA CTC ATT CCA AAA TAT GA-3´HPVE1 (nt 2336-2314)Numbering is according to the sequence of HPV16W12E (GenbankIDNr. AF125673)Table 2Socio-demographic & Reproductive characteristics of the study populationCharacteristicsFrequency/mean/medianPercentage (%)^a^Age(years)39.2 ± 9.1^b^ARV duration(years)3(IQR:1-6)Residence Rural15862.0 Urban9738.0SES Low11745.9 High13854.1H/STI NO21383.5 YES4216.5Parity Nullporous249.4  ≥ 1 child23190.6Level of education Lower level20981.7 High level4618.3CD4 cells/μl  \> 20013452.6 200-1009938.8  \< 100228.6Age at first intercourse Below 1818171.0 Above 187429.0Contraceptive use None16464.3 Hormonal6224.3 Condom2911.4Marital status Not married14456.5 Married11143.5ARV use None249.4  ≤ 6 months239.0  \> 6 months20881.6^a^mean, ^b^median

Data analysis {#Sec7}
-------------

The data were entered in the computer using Microsoft excel software and analysed using STATA version 11(STATA Corp LP, USA). Continuous variables were summarized as mean with standard deviation or as median with interquartile range whilst categorical variables were summarized as proportions. Socioeconomic status (SES) was defined using education, employment and business status of the participant. Log binomial regression for estimation of relative risk ratios was done followed by log multinomial regression analysis for the factors with *P* value of \<0.2. Cross tabulation was done to detect variables with collinearity. Factors found with collinearity were not subjected into log multinomial regression analysis. The chi square test and fisher's exact test were done to compare the distribution of HPV genotypes and SIL. Women with mixed genotypes were regarded as having HR genotype if HR genotype was present. Level of significance was measured by *p*-value whereby factors with *p*-values of less than 0.05 were considered statistically significant.

Results {#Sec8}
=======

Sociodemographic and obstetric characteristics {#Sec9}
----------------------------------------------

The mean age of enrolled women was 39.2 ± 9.14 years. A total of 111(43.5 %) were married and 46 (18.03 %) and 209(81.7 %) had higher and lower education respectively. Majority of the enrolled women 138(54.1 %) had high socioeconomic status. A total of 158(61.9 %) were residing in rural areas (Table [3](#Tab3){ref-type="table"}).Table 3Genotypes distribution of HPVHPV genotypesFrequencyLR/HRHPV 61LRHPV 1614HRHPV 188HRHPV 319HRHPV 334HRHPV 341HRHPV 3520HRHPV 402LRHPV 425LRHPV 4510HRHPV 471LRHPV 513HRHPV 5226HRHPV 535HRHPV 542LRHPV 565LRHPV 5821HRHPV 593HRHPV 665HRHPV 682HRHPV 731HRHPV 741LRHPV 824HRHPV 833LRHPV 903LRHPV 1031UnclassifiedTotal160

Prevalence of HPV {#Sec10}
-----------------

Of the 255 enrolled women, 138 (54.1 %, 95 % CI: 47-60) were found to have HPV DNA in their cervical cells. Out of 138 HPV infected women; 124 (48.6 %) were found to be infected with HR genotypes.

Genotypes distribution {#Sec11}
----------------------

In 138 HPV infected women; 26 genotypes were detected in various combinations. A total of 17/138(12.3 %) of HIV infected women had multiple HR genotypes. Of 26 genotypes, 17(65.4 %; 95%CI: 44.7-81.2) were HR while 9 (34.6 %, 95%CI: 14-49) were LR genotypes (*p* = 0.028). High risk genotypes detected were 16, 18, 31, 33, 34, 35, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 whereas LR genotypes detected were 6, 40, 42, 47, 54, 74, 83 and 90. The total frequency of the genotypes detected was 160 (Table 4); of these common HR genotypes were HPV-52(26, 16.3 %), HPV-58 (21, 13.1 %), HPV-35(20, 12.5 %) and HPV-16(14, 8.8 %).

Cervical squamous intraepithelial lesions (SIL) and genotypes distribution {#Sec12}
--------------------------------------------------------------------------

Out of the 255 women; 91(35.6 %) had SIL on cytological studies. Of 91 HIV infected women with SIL, 74 (81.3 %) had low grade SIL whilst 17(18.7 %) had high grade SIL. Eleven (64.7 %) of women with high grade SIL had positive HPV DNA in their cervical cells. Amongst these eleven women none-16 and non-18 genotypes were detected in 9(81.8 %) of them. Out of 124 women infected with HR genotypes, 55 (44.4 %) had any kind of SIL compared to only 31 (26.3 %) of 118 women with no HPV infection (*P* = 0.003) Fig. [1](#Fig1){ref-type="fig"}. Non-significant association between LR genotypes and SIL (5/14 vs. 31/118, *P* = 0.264) was observed. Of 17 women with multiple high risk genotypes, 1(5.8 %) had high grade SIL, 9(52.9 %) had low grade SIL and 7(41.2 %) had no SIL.Fig. 1High risk and low risk HPV genotypes in relation to cervical squamous intraepithelial lesions

Factors associated with HPV positivity among HIV infected women {#Sec13}
---------------------------------------------------------------

On log binomial regression analysis; women with good socioeconomic status, low CD4 counts, use of ARV ≤6 months and presence of SIL significant high risk of HPV infection as shown in Table [4](#Tab4){ref-type="table"}. Only women with low CD4 counts (RR: 1.2, 95 % CI: 1.05-1.35, *P* = 0.006) and presence of SIL (RR: 1.37, 95 % CI: 1.11-1.68, *P* = 0.005) remained with significant higher risk of being infected with HPV on log multinomial regression analysis.Table 4Log binomial and log multinomial regression analysis on the factors associated with HPV positivity among HIV infected womenCharacteristicsHPV positivity %Log binomial RR(95 % CI)*p* valueLog multinomial RR(95 % CI)*p*-valueAge  \> 45 (59)25(42.4 %)1  ≤ 45 (196)113(57.6 %)1.3 (.98- 1.87)0.061.26(0.89-1.4)0.266Residence Rural(158)85(53.8 %)1 Urban(97)53(54.64 %)1.01(0.80-1.28)0.896SES Low(117)54(46.2 %)1 High (138)84(60.9 %)1.31(1.04-1.67)0.0221.24(0.97-1.56)0.064H/STI NO (213)111(52.11 %)1 YES (42)27(64.29 %)1.23(0.95-1.599)0.1131.15(098-1.6)0.061Parity Nullporous (24)14 (58.33 %)1  ≥ 1 child (231)124 (53.68 %)0.92(0.64-1.32)0.650CD4  \> 200 (134)67(50.00 %)1 200-100(99)54(54.55 %)1.09(0.85-1.39)0.490  \< 100 (22)17(77.27 %)1.54(1.16-2.05)0.0031.20(1.05-1.35)0.006Age at first intercourse Below 18 (181)96(53.04 %)1 Above 18 (74)42(56.76 %)1.07(0.84-1.36)0.582Marital status Not married (144)76(52.78 %)1 Married (111)62(55.86 %)1.05(0.84-1.32)0.623^a^ARV use  \> 6 months(208)117(51.44 %)1  ≤ 6 months(23)16(69.5 %)1.28 (1.00-1.036)0.049SIL Absent (164)78(47.5 %)1 Present (91)60(65.9 %)1.49(1.18-1.87)0.0011.37(1.11-1.68)0.005Contraceptive use None (164)87(53.5 %)1 Hormonal (62)32 (51.6 %)0.9729(0.73-1.288)0.848 Condom(29)19 (65.5 %)1.23(0.914-1.66)0.219^a^ARV use was not subjected into multivariate analysis because of its collinearity with CD4 counts,

Discussion {#Sec14}
==========

Infection with oncogenic or HR human papillomavirus (HPV) genotypes is the major cause of cervical cancer. With the introduction of the quadrivalent HPV vaccine which prevents four HPV types: HPV 16 and 18, as well as HPV 6 and 11, that cause 90 % of genital warts the knowledge concerning the distribution of HPV genotypes has become increasingly public health concern \[[@CR21]\]. This study for the first time in Mwanza, Tanzania; documents high proportion of HIV infected women carrying varieties of HR genotypes similarly to previous reports \[[@CR6], [@CR22], [@CR23]\]. As in previous studies \[[@CR24]\], a significant proportion of women were uncommonly infected with multiple HR genotypes. These findings are in agreement with previous studies which reported uncommon HR genotypes infecting HIV infected women in developing countries \[[@CR4], [@CR22], [@CR25], [@CR26]\]. This calls for the need to include uncommon high risk genotypes in the current vaccine production especially for areas where HIV is endemic. The recently introduced a 9 valent (nanovalent) vaccine which includes HPV 52, 58, 45\[[@CR27]\]; the commonest genotypes detected in this study is of great advancement especially in sub Saharan Africa where HIV is endemic. The World health organization (WHO) should consider advocating replacing the current quadrivalent vaccine which is available in many centers in developing countries with nanovalent vaccine. One of the interesting findings in this study is the presence of HPV 35 genotype in relative high frequency which has been also found in other African countries \[[@CR22], [@CR26], [@CR28]\]. Unexpectedly, the recent introduced nanovalent vaccine does not include HPV 35 genotype emphasing the need to use epidemiological data for future vaccine development.

Variation of HPV genotypes can occur even within the country which might have implication in vaccine efficacy in the same country. As evidenced by the fact that in the current study, HPV-16 was not the commonest genotype among women with high grade SIL while in the previous study in Tanzania among HIV and non HIV infected women HPV-16 was the commonest genotype among women with high grade SIL \[[@CR12]\]. There is a possibility that the current existing HPV vaccines might have diverse efficacy especially in developing countries.

The current study confirms the clear association between HPV infection and SIL. As in previous studies \[[@CR29]--[@CR31]\], it was observed that women infected with HR genotypes were more likely to have SIL than non-infected and those infected with LR genotypes. Though none of the women with LR genotypes had high grade SIL; it was observed that 35.7 % of women infected with LR genotypes had low grade SIL, following these women over time to determine cervical changes and acquisition of other genotypes will provide important information regarding the role of LR genotypes and SIL. In addition, women with low CD4 counts (\<100) had significantly higher risk of acquiring HPV infection (low and high risk genotypes) as compared to their counterparts. Our findings are similar to what have been reported earlier \[[@CR11], [@CR32]--[@CR34]\]. This is due to immune suppression which poses the risk of opportunistic infections including HPV.

The major limitation of this study is inability to perform HIV viral load which could be used to correlate virological failure and HPV infection. In addition some important information such as tobacco use and information for those who declined were not collected. However the study established HPV prevalence and genotypes distribution among HIV infected women.

Conclusion {#Sec15}
==========

In present study, HIV seropositive women with low CD4 counts and various grades of cervical SIL are significantly infected with HR HPV genotypes. In countries where HIV is endemic the governments should consider addition of HPV vaccine in national immunization programme focusing on epidemiology of HPV genotypes. Data on the efficacy of the current vaccine in preventing SIL/cancer and warts are highly needed in developing countries for appropriate policy decision making.
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